ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Boryung Pharmaceutical Co., Ltd clinical trials

Part of Boryung Holdings Co., Ltd., which holds 50.66% as of 2026-06-10. Source

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 143 studies whose lead sponsor is Boryung Pharmaceutical Co., Ltd. 23 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2026.

Our grouping of 1 registry name, not the registry’s. See them and correct one ↓

Compare Boryung Pharmaceutical with Eli Lilly and CSPC Pharmaceutical Group →

Pipeline: 18 programs

Each counted once: 18 with a study Boryung Pharmaceutical Co., Ltd leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3

The 1 phase-3 program — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Boryung Pharmaceutical Co., Ltd’s own registered studies; Boryung Pharmaceutical Co., Ltd’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Boryung Pharmaceutical Co., Ltd’s studies test, most open studies first — 24 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 14 more

Coming up

7 of Boryung Pharmaceutical Co., Ltd’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 1D
  3. J’27
  4. 2F
  5. 1M
  6. A
  7. 1M
  8. J
  9. J
  10. A
  11. 2S
  12. O
  13. N

Add all 7 to your calendar (.ics) → With an account.

All 143 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now2316%Recruiting 16 · Not yet recruiting 7
  • Under way, not recruiting11%
  • Completed11883%
  • Stopped early11%

Phase

  • Phase 177
  • Phase 322
  • Phase 29
  • Phase 46
  • Early Phase 11

Where

  • Korea, Republic of121
  • Thailand1
  • United States1
  • Indonesia1

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 1424
  19. 25
  20. 726

By the year each study started; 6 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Boryung Pharmaceutical Co., Ltd.

  • Boryung Pharmaceutical Co., Ltd
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    143 studies

Related but not counted here: ViGenCell Inc. (affiliate).

Focus areas

Conditions Boryung Pharmaceutical Co., Ltd leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 143. Browse all 143 →